ALK and neoplasm: Fourteen of 47 (30%) ALK+ ALCL patients died (median follow-up time, 33.8 months; range, 0.3–382.8 months): 5 of 9 (56%) patients with CD25-low neoplasms and 9 of 38 (24%) patients with CD25-high neoplasms.